Healthcare Specialists GENUI and SHS Capital jointly invest in ROTOP, a leading manufacturer and CDMO of radiopharmaceuticals
|
Issuer: SHS Gesellschaft für Beteiligungsmanagement mbH
/ Key word(s): Investment/Private Equity
Healthcare Specialists GENUI and SHS Capital jointly invest in ROTOP, a leading manufacturer and CDMO of radiopharmaceuticals
Hamburg / Tübingen / Dresden, 15 January 2025 The market for radiopharmaceuticals has developed great momentum in recent years, outpacing for example the growth of traditional biotech sectors. One of the reasons for this is the medical and economic success of commercial radiopharmaceuticals, which has led to significant investments in the development of new drugs by biotech and pharmaceutical companies active in this field. ROTOP began expanding its CDMO offering two years ago to meet the increasing demand and to be able to cover the clinical and commercial need for batch capacities in the future. The investment by GENUI and SHS will now significantly expand the existing CDMO capacities given the growing market demand. Thanks to ROTOP's ties to the region, WMS Wachstumsfonds Mittelstand Sachsen was also won as an investor. "We are delighted to have won GENUI and SHS for our expansion plans. With their support, we will massively expand our development, laboratory and production capacities for CDMO services in radiopharmaceuticals, especially for radioactive ready-to-use patient doses for radioligand therapy (RLT). In the coming years, further extensive investments in new buildings, laboratories and production facilities are planned to meet the rapidly growing market demand," explains ROTOP CEO Jens Junker. "ROTOP's unique positioning in a very dynamically growing market led us to this investment. We are looking forward to supporting the management on the next big steps together with SHS," says Dr. Oliver Serg of GENUI. "We see great growth potential for the company as there is a clear demand for additional CDMO services in the radiopharmaceutical sector. We have been monitoring this market closely for a year and a half and are seeing an increase in financing and acquisitions of pharma companies. We hope our investment in ROTOP will significantly support an important growth phase in the field of radiodiagnostics and radiotherapeutics," adds SHS partner Dr. Cornelius Maas.
About ROTOP: ROTOP Pharmaka GmbH, founded in 2000 and based in Rossendorf near Dresden, is a market leader in the field of radiopharmaceutical products. The company's roots lie in the former Central Institute for Nuclear Research Rossendorf, which developed into one of the world's leading radiopharmaceutical centres from 1958 onwards. ROTOP manufactures cGMP-compliant radiopharmaceuticals for diagnostics and therapy in the fields of nuclear medicine and molecular imaging and distributes them in more than 40 countries worldwide. With around 150 employees, ROTOP is continuously expanding its product range through the development of new products and new strategic partnerships. More information: www.rotop-pharmaka.de About GENUI: GENUI is a private investment firm based in Hamburg/Germany. It was founded in 2014 by renowned entrepreneurs and experienced investment professionals, who have been investing in companies for over two decades and supporting them on their growth paths. GENUI follows the approach of “Good Entrepreneurship”, combining attractive returns and positive impact. The more than 30 GENUI entrepreneurs (founders and owners of companies such as BioNTech, Fressnapf, Adecco, Cancom and others) are actively and personally involved in all stages of the investment process. The focus of GENUI is on investments in market leaders in energy transition, health and digitalization. As a certified B Corp, GENUI pursues the strategic sustainability goal of supporting positive and measurable social or environmental impact. The investments are aligned with the United Nations' Sustainable Development Goals (SDGs). More information: www.genui.de About SHS Capital: The industry specialist SHS is a private equity provider founded in 1993 that makes investments in healthcare companies in Europe. Its investments focus on expansion financing, shareholder changes and succession situations. "Building European Healthcare Champions" is the investment philosophy according to which SHS finances and develops portfolio companies. The Tübingen-based investor acquires both minority and majority shareholdings. The national and international investors in SHS funds include pension funds, funds of funds, foundations, family offices, strategic investors, entrepreneurs and the SHS management team. The equity or equity-like investment of the AIF amounts to up to € 50 million. Volumes in excess of this can be realised with a network of co-investors. When making investment decisions, SHS attaches great importance to taking ESG aspects into account and has therefore committed itself to the UN PRI guidelines. SHS is currently investing from its sixth fund, which was launched in 2022 with a volume of around € 270 million. More information: www.shs-capital.eu Press contacts: For ROTOP
Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
